MedDataX Logo

Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients

NCT ID: NCT00876733

Last Updated: 2015-01-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

605 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-03-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with ARV, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine) will durably suppress viral load below the limit of detection or will maintain suppression of viral replication (HIV-RNA below limit of detection) achieved under previous anti-retroviral combination therapy after switch to combination treatment of Viramune (nevirapine) and ARV, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients

NCT00543803

HIV Infections
COMPLETED

Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune

NCT00979420

HIV Infections
COMPLETED

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

NCT01524900

HIV Infections
COMPLETED

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

NCT00002368

HIV Infections
COMPLETED PHASE3

Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS

NCT02191215

Acquired Immunodeficiency Syndrome
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV treatment

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male and female
* 18 years or older
* written informed consent

Exclusion Criteria

* Pregnant patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 14

Aachen, , Germany

Site Status

Boehringer Ingelheim Investigational Site 12

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 13

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 15

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 19

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 21

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 23

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 24

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 28

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 30

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 31

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 34

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 38

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 41

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 54

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 60

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 63

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 8

Berlin, , Germany

Site Status

Boehringer Ingelheim Investigational Site 58

Bochum, , Germany

Site Status

Boehringer Ingelheim Investigational Site 50

Chemnitz, , Germany

Site Status

Boehringer Ingelheim Investigational Site 53

Cologne, , Germany

Site Status

Boehringer Ingelheim Investigational Site 61

Cologne, , Germany

Site Status

Boehringer Ingelheim Investigational Site 48

Dortmund, , Germany

Site Status

Boehringer Ingelheim Investigational Site 27

Duisburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 49

Düsseldorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 62

Düsseldorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 9

Düsseldorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 32

Frankfurt, , Germany

Site Status

Boehringer Ingelheim Investigational Site 59

Frankfurt, , Germany

Site Status

Boehringer Ingelheim Investigational Site 65

Frankfurt, , Germany

Site Status

Boehringer Ingelheim Investigational Site 57

Freiburg im Breisgau, , Germany

Site Status

Boehringer Ingelheim Investigational Site 56

Fürth, , Germany

Site Status

Boehringer Ingelheim Investigational Site 29

Giessen, , Germany

Site Status

Boehringer Ingelheim Investigational Site 33

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 42

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 47

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 51

Hamburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 40

Hanover, , Germany

Site Status

Boehringer Ingelheim Investigational Site 43

Hanover, , Germany

Site Status

Boehringer Ingelheim Investigational Site 46

Hanover, , Germany

Site Status

Boehringer Ingelheim Investigational Site 6

Karlsruhe, , Germany

Site Status

Boehringer Ingelheim Investigational Site 25

Koblenz, , Germany

Site Status

Boehringer Ingelheim Investigational Site 37

Krefeld, , Germany

Site Status

Boehringer Ingelheim Investigational Site 11

Leipzig, , Germany

Site Status

Boehringer Ingelheim Investigational Site 52

Mainz, , Germany

Site Status

Boehringer Ingelheim Investigational Site 18

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 20

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 22

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 26

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 35

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 5

München, , Germany

Site Status

Boehringer Ingelheim Investigational Site 16

Münster, , Germany

Site Status

Boehringer Ingelheim Investigational Site 17

Münster, , Germany

Site Status

Boehringer Ingelheim Investigational Site 39

Münster, , Germany

Site Status

Boehringer Ingelheim Investigational Site 55

Münster, , Germany

Site Status

Boehringer Ingelheim Investigational Site 10

Neuss, , Germany

Site Status

Boehringer Ingelheim Investigational Site 36

Oldenburg, , Germany

Site Status

Boehringer Ingelheim Investigational Site 64

Osnabrück, , Germany

Site Status

Boehringer Ingelheim Investigational Site 7

Pforzheim, , Germany

Site Status

Boehringer Ingelheim Investigational Site 66

Potsdam, , Germany

Site Status

Boehringer Ingelheim Investigational Site 1

Stuttgart, , Germany

Site Status

Boehringer Ingelheim Investigational Site 3

Stuttgart, , Germany

Site Status

Boehringer Ingelheim Investigational Site 4

Stuttgart, , Germany

Site Status

Boehringer Ingelheim Investigational Site 45

Troisdorf, , Germany

Site Status

Boehringer Ingelheim Investigational Site 2

Wiesbaden, , Germany

Site Status

Boehringer Ingelheim Investigational Site 44

Wuppertal, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1100.1524

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
NCT03754803 COMPLETED
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
NCT00081588 COMPLETED PHASE2
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
NCT00158821 COMPLETED PHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311 ACTIVE_NOT_RECRUITING PHASE3
Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
NCT00819052 COMPLETED PHASE3
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
NCT06061081 TERMINATED PHASE2
Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort
NCT00618176 COMPLETED PHASE4
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
NCT00511368 COMPLETED PHASE2
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
NCT02187107 COMPLETED PHASE2
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
NCT00561925 COMPLETED PHASE3
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
NCT00002418 TERMINATED PHASE2
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
NCT00245739 APPROVED_FOR_MARKETING
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
NCT00001085 COMPLETED PHASE2
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
NCT00002323 COMPLETED NA
Multicenter, Safety Study Of Maraviroc
NCT00478231 COMPLETED PHASE3
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
NCT00002347 COMPLETED PHASE2
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
NCT00199979 UNKNOWN PHASE3
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
NCT00002381 COMPLETED PHASE1
Nevirapine + 3TC Based Maintenance Therapy for HIV Infection
NCT03223402 COMPLETED NA
A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients
NCT00046176 COMPLETED PHASE3
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
NCT02184078 COMPLETED PHASE4
TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options
NCT00115050 COMPLETED PHASE3
Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
NCT00127959 COMPLETED PHASE4
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
NCT00002324 COMPLETED PHASE2
Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.
NCT00967187 COMPLETED PHASE2